Identification of CCL20 as a Key Biomarker of Inflammatory Responses in the Pathogenesis of Intracerebral Hemorrhage

Zheng, Zong-Qing; Yuan, Gui-Qiang; Zhang, Guo-Guo; Chen, Yanting; Nie, Qian-Qian; Wang, Zhong

doi:10.1007/s10753-023-01807-4

Cited by 7 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CCL20 reportedly exhibits promising potential as a diagnostic biomarker and a therapeutic target in experimental models of cranial brain injury 28 . Furthermore, it has been identified as a central gene in intracerebral hemorrhage 29 and a key inflammatory response biomarker 30 . Meanwhile, PDK4 has been proposed as a potential biomarker in patients with renal ischemia 31 and is considered an important gene related to cell death in females with IS 32 .…”

Section: Discussionmentioning

confidence: 99%

Potential diagnostic biomarkers for immunogenic cell death in elderly female patients with ischemic stroke: identification and analysis

Qin,

Li,

Cao

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Ischemic stroke (IS) is of increasing concern given the aging population and prevalence of unhealthy lifestyles, with older females exhibiting higher susceptibility. This study aimed to identify practical diagnostic markers, develop a diagnostic model for immunogenic cell death (ICD)-associated IS, and investigate alterations in the immune environment caused by hub genes. Differentially expressed genes associated with ICD in IS were identified based on weighted gene co-expression network analysis and the identification of significant modules. Subsequently, machine learning algorithms were employed to screened hub genes, which were further assessed using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis. A nomogram mode lwas then constructed for IS diagnosis, and its diagnostic value was assessed using a receiver operating characteristic curve. Finally, alterations in immune cell infiltration were assessed within patients with IS, and the pan-cancer expression patterns of hub genes were evaluated. Three hub genes associated with ICD (PDK4, CCL20, and FBL) were identified. The corresponding nomogram model for IS diagnosis could effectively identify older female patients with IS (area under the curve (AUC) = 0.9555). Overall, the three hub genes exhibit good diagnostic value (AUC > 0.8). CCL20 and FBL are significantly associated with the extent of immune cells infiltration. Moreover, a strong link exists between hub gene expression and pan-cancer prognosis. Cumulatively, these results indicate that ICD-related hub genes critically influence IS progression in older females, presenting novel diagnostic and therapeutic targets for personalized treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential diagnostic biomarkers for immunogenic cell death in elderly female patients with ischemic stroke: identification and analysis

Qin,

Li,

Cao

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Moreover, activation of the CCL20-CCR6 axis seems to be important in the development of dry eye disease, which affects approximately 37% of TBI patients [359]. Interestingly, a recent study reported that CCL20 expression is upregulated after ICH in mice [356] and rats [360] and that chemokine was suggested as a potential target for pharmacological intervention. The algesic properties of CCL20 have not yet been documented.…”

Section: Ccr6-endogenous Ligandsmentioning

confidence: 99%

CC Chemokine Family Members’ Modulation as a Novel Approach for Treating Central Nervous System and Peripheral Nervous System Injury—A Review of Clinical and Experimental Findings

Ciechanowska,

Mika

2024

IJMS

View full text Add to dashboard Cite

Despite significant progress in modern medicine and pharmacology, damage to the nervous system with various etiologies still poses a challenge to doctors and scientists. Injuries lead to neuroimmunological changes in the central nervous system (CNS), which may result in both secondary damage and the development of tactile and thermal hypersensitivity. In our review, based on the analysis of many experimental and clinical studies, we indicate that the mechanisms occurring both at the level of the brain after direct damage and at the level of the spinal cord after peripheral nerve damage have a common immunological basis. This suggests that there are opportunities for similar pharmacological therapeutic interventions in the damage of various etiologies. Experimental data indicate that after CNS/PNS damage, the levels of 16 among the 28 CC-family chemokines, i.e., CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL11, CCL12, CCL17, CCL19, CCL20, CCL21, and CCL22, increase in the brain and/or spinal cord and have strong proinflammatory and/or pronociceptive effects. According to the available literature data, further investigation is still needed for understanding the role of the remaining chemokines, especially six of them which were found in humans but not in mice/rats, i.e., CCL13, CCL14, CCL15, CCL16, CCL18, and CCL23. Over the past several years, the results of studies in which available pharmacological tools were used indicated that blocking individual receptors, e.g., CCR1 (J113863 and BX513), CCR2 (RS504393, CCX872, INCB3344, and AZ889), CCR3 (SB328437), CCR4 (C021 and AZD-2098), and CCR5 (maraviroc, AZD-5672, and TAK-220), has beneficial effects after damage to both the CNS and PNS. Recently, experimental data have proved that blockades exerted by double antagonists CCR1/3 (UCB 35625) and CCR2/5 (cenicriviroc) have very good anti-inflammatory and antinociceptive effects. In addition, both single (J113863, RS504393, SB328437, C021, and maraviroc) and dual (cenicriviroc) chemokine receptor antagonists enhanced the analgesic effect of opioid drugs. This review will display the evidence that a multidirectional strategy based on the modulation of neuronal–glial–immune interactions can significantly improve the health of patients after CNS and PNS damage by changing the activity of chemokines belonging to the CC family. Moreover, in the case of pain, the combined administration of such antagonists with opioid drugs could reduce therapeutic doses and minimize the risk of complications.

show abstract

“…Additionally, CXCL12 enhances the proliferation, migration, adhesion, and vascular repair capabilities of BECs after ICH 89 . CCL20 emerges as an inflammatory biomarker following ICH, providing a promising target for anti‐inflammatory interventions 95 . The levels of several other members of the CXCL family, including CXCL9, CXCL11, CXCL17, and CXCL21, also increased after ICH, 20 though research on these factors remains limited.…”

Section: The Influence Of Cytokines On Bbbmentioning

confidence: 99%

Immune‐mediated disruption of the blood–brain barrier after intracerebral hemorrhage: Insights and potential therapeutic targets

Jia,

Peng,

Fan

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

AimsIntracerebral hemorrhage (ICH) is a condition that arises due to the rupture of cerebral blood vessels, leading to the flow of blood into the brain tissue. One of the pathological alterations that occurs during an acute ICH is an impairment of the blood–brain barrier (BBB), which leads to severe perihematomal edema and an immune response.DiscussionA complex interplay between the cells of the BBB, for example, pericytes, astrocytes, and brain endothelial cells, with resident and infiltrating immune cells, such as microglia, monocytes, neutrophils, T lymphocytes, and others accounts for both damaging and protective mechanisms at the BBB following ICH. However, the precise immunological influence of BBB disruption has yet to be richly ascertained, especially at various stages of ICH.ConclusionThis review summarizes the changes in different cell types and molecular components of the BBB associated with immune‐inflammatory responses during ICH. Furthermore, it highlights promising immunoregulatory therapies to protect the integrity of the BBB after ICH. By offering a comprehensive understanding of the mechanisms behind BBB damage linked to cellular and molecular immunoinflammatory responses after ICH, this article aimed to accelerate the identification of potential therapeutic targets and expedite further translational research.

show abstract

Identification of CCL20 as a Key Biomarker of Inflammatory Responses in the Pathogenesis of Intracerebral Hemorrhage

Cited by 7 publications

References 29 publications

Potential diagnostic biomarkers for immunogenic cell death in elderly female patients with ischemic stroke: identification and analysis

Potential diagnostic biomarkers for immunogenic cell death in elderly female patients with ischemic stroke: identification and analysis

CC Chemokine Family Members’ Modulation as a Novel Approach for Treating Central Nervous System and Peripheral Nervous System Injury—A Review of Clinical and Experimental Findings

Immune‐mediated disruption of the blood–brain barrier after intracerebral hemorrhage: Insights and potential therapeutic targets

Contact Info

Product

Resources

About